Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week High – Still a Buy?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price hit a new 52-week high during trading on Thursday . The company traded as high as $105.62 and last traded at $108.2740, with a volume of 102678 shares traded. The stock had previously closed at $99.27.

Analyst Upgrades and Downgrades

A number of research firms have commented on MNPR. Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. UBS Group set a $105.00 price target on shares of Monopar Therapeutics in a report on Monday, June 29th. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $105.00 price objective on shares of Monopar Therapeutics in a research report on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $108.75.

Monopar Therapeutics Trading Up 9.1%

The company’s 50-day moving average is $68.94 and its 200 day moving average is $63.32. The stock has a market capitalization of $725.27 million, a PE ratio of -56.66 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. Sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after acquiring an additional 30,042 shares during the last quarter. RA Capital Management L.P. grew its stake in Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after purchasing an additional 156,000 shares during the last quarter. Siren L.L.C. increased its holdings in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares during the period. Finally, Wellington Management Group LLP purchased a new position in shares of Monopar Therapeutics in the third quarter worth about $18,904,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.